Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 1;86(6):3608-3614.
doi: 10.1097/MS9.0000000000002113. eCollection 2024 Jun.

Role of erythropoietin in the treatment of Alzheimer's disease: the story so far

Pavan Kumar Reddy Kalluru  1 , Sushmitha Bhavanthi  2 , Shambhavi Vashist  3 , Ravikishore Reddy Gopavaram  4 , Mahesh Mamilla  1 , Shriya Sharma  4 , Chethan Raj Gundoji  2 , Sumaja Reddy Goguri  5
Affiliations
Review

Role of erythropoietin in the treatment of Alzheimer's disease: the story so far

Pavan Kumar Reddy Kalluru et al. Ann Med Surg (Lond). .

Abstract

This review aims to explore the potential of erythropoietin, a glycopeptide hormone, as a treatment option for Alzheimer's disease, which is the commonest cause of dementia. Despite years of focus and research, therapeutic options for Alzheimer's disease are not yet completely satisfactory. And as people age, they are likely to develop Alzheimer's Disease, further pressuring the healthcare system. So, it is definite to develop treatment options that meet superior outcomes with minimal negative effects. A comprehensive review of the literature was conducted in PubMed and Google Scholar using a combination of keywords, including Alzheimer's disease, dementia, erythropoietin, and neuroprotection. Search results were assessed for relevance before using the data for this study. The beneficial implications of erythropoietin as a therapeutic option have been explored, along with the side effects and mechanisms of erythropoietin in Alzheimer's disease. Overall, the authors' review indicates that erythropoietin presents a promising avenue for mitigating the progression of Alzheimer's disease, with minimal associated side effects.

Keywords: Alzheimer’s disease; dementia; erythropoietin; neurodegenerative diseases; neuroprotection.

PubMed Disclaimer

Conflict of interest statement

None of the authors have conflicts of interest to disclose.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Figures

Figure 1
Figure 1
Schematic presentation of possibles mechanism by which erythropoietin exerts it effects.
See this image and copyright information in PMC

References

    1. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 2016;8:595–608. - PMC - PubMed
    1. Zhang XX, Tian Y, Wang ZT, et al. . The epidemiology of Alzheimer’s disease modifiable risk factors and prevention. J Prev Alzheimers Dis 2021;8:313–321. - PubMed
    1. Alzheimer’s Disease International . World Alzheimer Report 2019.Availableathttps://www.alz.co.uk/research/WorldAlzheimerReport2019.pdf .
    1. World Health Organization . Dementia. Accessed on September 08, 2023. https://www.who.int/news-room/fact-sheets/detail/dementia
    1. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement 2022;18:700–789. doi:10.1002/alz.12638 - DOI - PubMed